Stempeutics concludes patient enrollment for Phase 3 cell therapy trial for diabetic foot ulcer
Cipla has in-licensed Stempeucel-DFU product for Sales & Marketing in India
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Stempeutics Research
Cipla continues to expand focus on therapy areas of promising growth through deals: GlobalData
In recent years, Cipla also had agreements with Roche India, Mannkind USA, Stempeutics Research, Novartis and Luye Pharma to…
Stempeutics out licenses its stem cell product to Cipla for treating Diabetic Foot Ulcer
Under this agreement, Cipla will get the exclusive marketing rights for five years in India for DFU product with Stempeutics…
Stempeutics to launch stem cell device in India by mid 2016
The device will be used for later treatment of osteoarthritis and diabetic foot ulcer to even breast augmentation surgery…
Stempeutics receives ODD in the European Union for Stempeucel
Stempeucel is used in the treatment of Thromboangiitis Obliterans
Stempeutics receives ATMP classification from EMA for its novel stem cell drug Stempeucel
The first stem cell drug-based on pooling technology to be granted ATMP classification Stempeutics Research, a group company of…